Opipari Anthony W. 4
4 · Odyssey Therapeutics, Inc. · Filed May 11, 2026
Research Summary
AI-generated summary of this filing
Odyssey (ODTX) Interim CMO Anthony Opipari Receives ~278K Share Awards
What Happened Anthony W. Opipari, Interim Chief Medical Officer and EVP, Translational Medicine at Odyssey Therapeutics (ODTX), received awards of derivative securities totaling 277,980 shares (250,203 + 27,777) on May 7, 2026 (grants at $0.00). On May 11, 2026 he converted/exercised multiple derivative instruments into common stock (several conversion/exercise entries totaling additional converted shares) and had 4 shares withheld/sold to cover exercise/tax obligations at $18.00 per share for $72. Most conversions/exercises are reported as derivative conversions (no cash paid in filing).
Key Details
- Grant date: 2026-05-07 — Awards of 250,203 and 27,777 derivative shares, $0.00 exercise price (total 277,980 shares).
- Conversion/exercise date(s): 2026-05-11 — multiple conversions/exercises reported (examples in filing: 6,965; 541; 18,531; 11,083; 20,000; 17,545; 5,263 shares listed across entries).
- Tax/withholding: 4 shares disposed at $18.00 each to satisfy exercise/tax withholding, net proceeds $72 (footnote F6).
- Footnotes: automatic conversions of Series A–D preferred and certain warrants into common stock before the IPO (F1–F5); reverse 1-for-9.7170 split noted (F7); some awards/options carry time-based monthly vesting starting June 7, 2026 (F8) and a market-cap milestone vesting condition at $1.5B VWAP (F9).
- Shares owned after transaction: not specified in the supplied summary of this Form 4.
- Filing timeliness: Form filed 2026-05-11 for transactions dated 2026-05-07 and 2026-05-11 — appears timely (filed within the SEC’s 2-business-day window).
Context These filings primarily report derivative awards and the conversion/exercise of previously held derivative securities (including automatic conversions related to preferred stock and warrants around the issuer’s IPO). The small disposition (4 shares) was to cover withholding/exercise obligations (net exercise), not an ordinary open-market sale. The awards are acquisitions (not sales), and no significant cash proceeds to the insider are shown besides the $72 withholding.
Insider Transaction Report
- Conversion
Common Stock
[F1][F2][F3][F4]2026-05-11+6,965→ 6,965 total - Exercise/Conversion
Common Stock
[F5]2026-05-11+541→ 7,506 total - Tax Payment
Common Stock
[F5][F6]2026-05-11$18.00/sh−4$72→ 7,502 total - Conversion
Series A Convertible Preferred Stock
[F1][F7]2026-05-11−18,531→ 0 total→ Common Stock (1,907 underlying) - Conversion
Series B Convertible Preferred Stock
[F2][F7]2026-05-11−11,083→ 0 total→ Common Stock (1,194 underlying) - Conversion
Series C Convertible Preferred Stock
[F3][F7]2026-05-11−20,000→ 0 total→ Common Stock (2,058 underlying) - Conversion
Series D Convertible Preferred Stock
[F4][F7]2026-05-11−17,545→ 0 total→ Common Stock (1,806 underlying) - Award
Stock Option (Right to Buy)
[F8]2026-05-07+250,203→ 250,203 totalExercise: $18.00Exp: 2036-05-06→ Common Stock (250,203 underlying) - Award
Stock Option (Right to Buy)
[F9]2026-05-07+27,777→ 27,777 totalExercise: $18.00Exp: 2036-05-06→ Common Stock (27,777 underlying) - Exercise/Conversion
Series D Warrants (Right to Buy)
[F5]2026-05-11−5,263→ 0 totalExercise: $0.10→ Common Stock (541 underlying)
Footnotes (9)
- [F1]The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
- [F2]The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
- [F3]The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
- [F4]The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
- [F5]The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
- [F6]Pursuant to the terms of the warrants, the Issuer withheld 4 warrant shares to pay the exercise price in connection with the net exercise.
- [F7]Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
- [F8]Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date.
- [F9]Option vests upon the first occurrence of the total market capitalization of the Issuer being equal to or in excess of $1,500,000,000, based on a 5-day volume-weighted average price of a share of Common Stock as traded on the Nasdaq Capital Market, subject to the Reporting Person's continued service on such vesting date.